Developmental Medicine and Child Neurology最新文献

Selective Control Assessment of the Lower Extremity for Infants and Toddlers (Mini-SCALE): Development and validation of a clinical assessment. 婴幼儿下肢选择性控制评估（迷你量表）：临床评估的发展和验证。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-08-02 DOI: 10.1111/dmcn.16415

Loretta A Staudt, Barbara Sargent, Lillian Chen, Eileen G Fowler

{"title":"Selective Control Assessment of the Lower Extremity for Infants and Toddlers (Mini-SCALE): Development and validation of a clinical assessment.","authors":"Loretta A Staudt, Barbara Sargent, Lillian Chen, Eileen G Fowler","doi":"10.1111/dmcn.16415","DOIUrl":"https://doi.org/10.1111/dmcn.16415","url":null,"abstract":"Aim: To investigate the validity of Selective Control Assessment of the Lower Extremity for Infants and Toddlers (Mini-SCALE), an adaptation of Selective Control Assessment of the Lower Extremity (SCALE), in young children aged from 3 months to less than 4 years.Method: Mini-SCALE was modified from SCALE and reviewed by 16 experienced clinicians to establish content validity. For convergent validity, Mini-SCALE was compared to the Developmental Assessment of Young Children, Second Edition, Gross Motor subdomain (DAYC-2 GM) for 50 participants (aged 4-46 months, 29 males) with cerebral palsy (CP) (n = 20), at risk for CP (n = 9), and typically developing participants (n = 21) using a prospective cross-sectional design. For known-group validity, the scores of children with or at risk for CP were compared to typically developing children using the Welch's two-sample t-test.Results: Content validity was strong with 96.6% (range = 75%-100%) expert agreement on 54 statements about content, administration, and grading. Convergent validity was strong between Mini-SCALE and the DAYC-2 GM (Spearman's rank correlation coefficient, rs = 0.80; p < 0.001). Mini-SCALE discriminated between children with or at risk for CP and typically developing children (p < 0.001).Interpretation: Mini-SCALE is a valid measure of selective motor control for young children with or at risk for CP.","PeriodicalId":50587,"journal":{"name":"Developmental Medicine and Child Neurology","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural history and variants in neuronal ceroid lipofuscinoses: Uncoupling genotype and phenotype. 神经元类脂褐变的自然历史和变异：解偶联基因型和表型。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-08-02 DOI: 10.1111/dmcn.16442

Sara Elizabeth Mole

引用次数: 0

Clinical features and outcomes of paediatric probable antibody-negative autoimmune encephalitis. 小儿可能的抗体阴性自身免疫性脑炎的临床特点和结局。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-08-02 DOI: 10.1111/dmcn.16456

Hye Jin Kim, Jong Ho Cha, Woojoong Kim, Soo Yeon Kim, Anna Cho, Hunmin Kim, Jong-Hee Chae, Jieun Choi, Ki Joong Kim, Byung Chan Lim

{"title":"Clinical features and outcomes of paediatric probable antibody-negative autoimmune encephalitis.","authors":"Hye Jin Kim, Jong Ho Cha, Woojoong Kim, Soo Yeon Kim, Anna Cho, Hunmin Kim, Jong-Hee Chae, Jieun Choi, Ki Joong Kim, Byung Chan Lim","doi":"10.1111/dmcn.16456","DOIUrl":"https://doi.org/10.1111/dmcn.16456","url":null,"abstract":"Aim: To evaluate the clinical features and outcomes of paediatric probable antibody-negative autoimmune encephalitis.Method: This retrospective cohort study included 66 patients (43 males and 23 females) with probable antibody-negative autoimmune encephalitis. Clinical outcomes were assessed using the modified Rankin Scale (mRS) and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE). A good 1-year clinical outcome was defined as an mRS score of 0 to 2 and a CASE score of 0 to 4. Seizure outcomes at 1 year were evaluated separately.Results: Median age at onset was 10 years (interquartile range [IQR] 5 years 4 months-12 years) and the median follow-up was 24 months (IQR = 12.5-49.8). Common neurological symptoms included altered mentality (92.4%) and seizures (84.8%). Most patients (89.4%) received first-line immunotherapy (methylprednisolone or intravenous immunoglobulins), while 33.3% received second-line immunotherapy (rituximab with or without tocilizumab). At 1 year, 95.1% (58 of 61) achieved good clinical outcomes according to the mRS and 91.8% (56 of 61) according to CASE. However, 44.2% had persistent seizures, 32.8% had cognitive problems, and 27.9% had behavioural problems. Neither immunotherapy timing nor second-line immunotherapy affected outcomes. Status epilepticus was the only risk factor for persistent seizures at 1 year (odds ratio = 4.16; 95% confidence interval = 1.16-14.92).Interpretation: Although most children with antibody-negative autoimmune encephalitis showed favourable clinical outcomes after immunotherapy, persistent seizures and cognitive and behavioural deficits remained. Absence of status epilepticus predicted better seizure outcomes.","PeriodicalId":50587,"journal":{"name":"Developmental Medicine and Child Neurology","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Motor outcomes and visual function in adults born preterm with very low birthweight. 极低出生体重早产儿成人的运动结果和视觉功能。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-08-02 DOI: 10.1111/dmcn.16438

Silje D Benum, Urd E Svennevig, Anna Fivelstad, Anna P M Jørgensen, Maarit Kulmala, Kristina A D Aakvik, Stian Lydersen, Anna Majander, Tora S Morken, Eero Kajantie, Kari Anne I Evensen

{"title":"Motor outcomes and visual function in adults born preterm with very low birthweight.","authors":"Silje D Benum, Urd E Svennevig, Anna Fivelstad, Anna P M Jørgensen, Maarit Kulmala, Kristina A D Aakvik, Stian Lydersen, Anna Majander, Tora S Morken, Eero Kajantie, Kari Anne I Evensen","doi":"10.1111/dmcn.16438","DOIUrl":"https://doi.org/10.1111/dmcn.16438","url":null,"abstract":"Aim: To examine whether being born preterm (<37 weeks' gestation) with very low birthweight (VLBW ≤1500 g) is associated with poorer outcomes in mid-adulthood, and whether this association is mediated by visual function.Method: In two prospective cohorts from Finland and Norway, motor outcomes and visual function were assessed in 118 adults born with VLBW and 147 term-born control individuals. Risk differences (95% confidence intervals [CI]) were assessed for overall and gross motor difficulties (<5th centile on Bruininks Motor Ability Test Short Form and Revised High-level Mobility Assessment Tool) and fine motor difficulties (>2 standard deviations on the Grooved Pegboard and Trail Making Test-5). We investigated the association between VLBW and motor outcomes with best-corrected visual acuity (BCVA) as mediator.Results: Overall motor difficulties were present in 34.7% of the VLBW and 4.8% of the control groups (risk difference 29.9%; 95% CI 20.6-39.1). Risk differences were 2.6% (-1.1 to 6.2) to 12.3% (4.9-19.7) for fine motor difficulties and 15.5% (7.5-23.6) for gross motor difficulties. BCVA mediated the association between VLBW and fine motor difficulties as well as continuous overall, fine, and gross motor scores.Interpretation: Whether the findings reflect a causal pathway between visual function and motor outcomes, or a shared aetiology, cannot be answered in this study.","PeriodicalId":50587,"journal":{"name":"Developmental Medicine and Child Neurology","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144765767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing and enhancing visual responses in children with severe cerebral impairment. 评估和增强严重脑损伤儿童的视觉反应。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-07-31 DOI: 10.1111/dmcn.16451

Richard Bowman

引用次数: 0

In developmental disability, parenting is a dance led by the child. 在发育性残疾中，养育子女是由孩子主导的舞蹈。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-07-31 DOI: 10.1111/dmcn.16457

Peter Rosenbaum, Elizabeth Marie Chambers

引用次数: 0

Motor change, comorbidities, and communication: Toward a more inclusive and realistic description of cerebral palsy. 运动改变、合并症和交流：对脑瘫的更包容和更现实的描述。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-07-31 DOI: 10.1111/dmcn.16439

Cláudia Alcantara de Torre, Raquel de Paula Carvalho

引用次数: 0

Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter study. 肉毒杆菌毒素A治疗小儿下肢痉挛的有效性和安全性：一项前瞻性、观察性、多中心的IV期研究。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-07-31 DOI: 10.1111/dmcn.16428

Mark E Gormley, Edward Dabrowski, Mauricio R Delgado, Ann Tilton, Asare Christian, Sarah Helen Evans, Anne-Sophie Grandoulier, Jumaah Goldberg

{"title":"Effectiveness and safety of abobotulinumtoxinA in pediatric lower limb spasticity: A phase IV, prospective, observational, multicenter study.","authors":"Mark E Gormley, Edward Dabrowski, Mauricio R Delgado, Ann Tilton, Asare Christian, Sarah Helen Evans, Anne-Sophie Grandoulier, Jumaah Goldberg","doi":"10.1111/dmcn.16428","DOIUrl":"https://doi.org/10.1111/dmcn.16428","url":null,"abstract":"Aim: To assess the longitudinal attainment of patient-centered, function-related Goal Attainment Scaling Total (GAS T)-score after repeated abobotulinumtoxinA (AboBoNT-A) injections over a period of up to 30 months and up to 10 cycles.Method: In this prospective observational study, the investigators' clinical practices recruited patients aged 2 to 17 years with pediatric lower limb spasticity (PLLS). GAS T-scores were assessed for each injection, and goals could be redefined at each visit; scores of 50 reflected goal achievement. Adverse events were recorded.Results: Of 210 patients in the effectiveness population, 171 had cerebral palsy and 163 were previously treated with a botulinum neurotoxin. Available Gross Motor Function Classification System levels showed that 31.3% (61 out of 195) of patients were non-ambulatory. Mean (SD) cumulative GAS T-score was 51.1 (9.3) across the study duration; 75.2% achieved their primary goals. GAS T-scores were comparable between BoNT-naïve and previously treated patients and between age groups, but higher in the ambulatory than the non-ambulatory subgroup. Injection guidance techniques were used in more than 70% of patients in cycles 1 to 6. Of 242 patients in the safety population, 102 reported 392 treatment-emergent adverse events, including 15 reporting 35 treatment-related adverse events. Adverse events were generally mild to moderate.Interpretation: Overall, goals were achieved as, or better than, expected in most patients. AboBoNT-A was well tolerated, with a low incidence of treatment-related adverse events. These results indicate that AboBoNT-A is an effective treatment option, with a positive risk-benefit profile, for patients with PLLS across disability levels.","PeriodicalId":50587,"journal":{"name":"Developmental Medicine and Child Neurology","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global evidence of disability: What is the economic context? 全球残疾证据：经济背景是什么？

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-07-31 DOI: 10.1111/dmcn.16441

Arnab Seal

引用次数: 0

Reframing cerebral palsy for a truly inclusive future. 为真正包容的未来重塑脑瘫。

IF 4.3 2区医学

Developmental Medicine and Child Neurology Pub Date : 2025-07-31 DOI: 10.1111/dmcn.16443

Rafael Bonfim

引用次数: 0